1. Home
  2. GROV vs RLYB Comparison

GROV vs RLYB Comparison

Compare GROV & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grove Collaborative Holdings Inc.

GROV

Grove Collaborative Holdings Inc.

HOLD

Current Price

$1.13

Market Cap

45.8M

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$14.08

Market Cap

43.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GROV
RLYB
Founded
2016
2018
Country
United States
United States
Employees
295
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.8M
43.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GROV
RLYB
Price
$1.13
$14.08
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$1.60
N/A
AVG Volume (30 Days)
57.3K
254.3K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.00
52 Week Low
$1.03
$0.27
52 Week High
$1.60
$14.60

Technical Indicators

Market Signals
Indicator
GROV
RLYB
Relative Strength Index (RSI) 38.32 90.02
Support Level $1.06 $0.54
Resistance Level $1.58 N/A
Average True Range (ATR) 0.06 0.52
MACD -0.01 0.55
Stochastic Oscillator 22.58 83.56

Price Performance

Historical Comparison
GROV
RLYB

About GROV Grove Collaborative Holdings Inc.

Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: